The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
Due to the widespread use of tyrosine kinase inhibitors (TKIs), which have largely supplanted cytotoxic chemotherapy as the first-line therapeutic choice for patients with advanced non-small cell lung cancer (NSCLC) who have oncogene driver mutations, advanced NSCLC patients with oncogene driver mut...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2022-05-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fonc.2022.863715/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|